Patients with oestrogen receptor (ER)-positive, HER2-positive ABC can also be offered endocrine therapy combined with HER2-directed therapy as first-line treatment of metastatic disease in patients wishing to avoid or defer exposure to chemotherapy, although rapidly progressive disease or visceral crisis are contraindications to that approach. Here, ERBB2 is linked to metastatic neoplasm.